HRP20100128T1 - Tumoru pridruženi peptid koji se slobodno veže na molekule humanog leukocitnog antigena (hla) klase ii - Google Patents
Tumoru pridruženi peptid koji se slobodno veže na molekule humanog leukocitnog antigena (hla) klase ii Download PDFInfo
- Publication number
- HRP20100128T1 HRP20100128T1 HR20100128T HRP20100128T HRP20100128T1 HR P20100128 T1 HRP20100128 T1 HR P20100128T1 HR 20100128 T HR20100128 T HR 20100128T HR P20100128 T HRP20100128 T HR P20100128T HR P20100128 T1 HRP20100128 T1 HR P20100128T1
- Authority
- HR
- Croatia
- Prior art keywords
- tumor
- peptide
- amino acid
- nucleic acid
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Tumoru pridruženi peptid koji se sastoji od aminokiselinskog slijeda prema Identifikacijskom broju slijeda 42. Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Tumoru pridruženi peptid koji se sastoji od aminokiselinskog slijeda prema Identifikacijskom broju slijeda 42.
2. Tumoru pridruženi peptid prema koji se sastoji od aminokiselinskog slijeda prema Identifikacijskom broju slijeda 42, gdje su jedan ili dva aminokiselinska ostatka izmijenjeni zamjenom bočnih lanaca s drugim aminokiselinskim ostatkom koji se javlja u prirodi, tako da je peptid još uvijek sposoban za vezivanje na HLA molekulu na jednak način kao i spomenuti peptid na Identifikacijski broj slijeda 42.
3. Tumoru pridružen peptid prema bilo kojem od Zahtjeva 1 ili 2, gdje peptid uključuje veze koje nisu peptidne.
4. Nukleinska kiselina koja se sastoji od niza koji kodira peptid prema jednom od Zahtjeva 1 do 3.
5. Nukleinska kiselina prema Zahtjevu 4 koja je DNK, cDNK, PNK, CNK, RNK ili kombinacija navedenih.
6. Vektor ekspresije sposoban za ekspresiju nukleinske kiseline prema Zahtjevu 4 ili 5.
7. Stanica domaćina koja sadrži nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 gdje spomenuta stanica domaćina nije stanica humanog embrija.
8. Metoda proizvodnje tumoru pridruženog peptida prema bilo kojem od Zahtjeva 1 ili 2, pri čemu se metoda sastoji od kultiviranja stanice domaćina prema Zahtjevu 7 te izolacije peptida iz stanice domaćina ili njezinog hranidbenog medija.
9. Farmaceutski sastav koji obuhvaća tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevu 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 te farmaceutski prikladan nosač, poželjno u obliku cjepiva protiv raka, a po izboru može sadržavati barem jedan prikladan adjuvans.
10. Tumoru pridruženi peptid prema bilo kojem od Zahtjeva 1 do 3, nukleinsku kiselinu prema Zahtjevima 4 ili 5 ili vektor ekspresije prema Zahtjevu 6 za upotrebu u medicini.
11. Upotreba tumoru pridruženog peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevima 4 ili 5 ili vektora ekspresije prema Zahtjevu 6 u proizvodnji lijekova za eliminaciju stanica raka kod pacijenta, a koje abnormalno eksprimiraju polipeptid sastavljen od aminokiselinskog slijeda prikazanog u bilo kojem od Zahtjeva 1 ili 2.
12. Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 ili 5 ili vektora ekspresije prema Zahtjevu 6 za proizvodnju lijekova za indukciju imunološkog odgovora, posebice staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahtjeva 1 ili 2.
13. In vitro metoda za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), pri čemu se metoda sastoji od in vitro doticaja CTL-a s uklopljenim antigenima MHC molekula razreda II, prikazanim na površini prikladne stanice koja prikazuje antigen u vremenskom razdoblju dovoljnom za aktivaciju spomenutog CTL-a na antigen-specifičan način, gdje je spomenuti antigen peptid iz bilo kojeg od Zahtjeva 1 ili 2.
14. Metoda prema Zahtjevu 13, gdje je antigen uklopljen u MHC molekule razreda II prikazan na površini prikladne stanice koja prikazuje antigen putem kontakta dovoljne količine antigena sa spomenutom stanicom.
15. Metoda iz Zahtjeva 13, gdje se stanica koja prikazuje antigen sastoji od vektora ekspresije prema Zahtjevu 6.
16. Aktivirani citotoksični T limfociti (CTL), dobiveni metodom prema bilo kojem od Zahtjeva 13 do 15, a koji selektivno prepoznaju stanicu koja abnormalno eksprimira polipeptid sastavljen od aminokiselinskog slijeda spomenutog u bilo kojem od Zahtjeva 1 ili 2.
17. Receptor T stanica (TCR) koji prepoznaje stanicu koja abnormalno eksprimira polipeptid sastavljen od aminokiselinskog slijeda spomenutog u bilo kojem od Zahtjeva 1 ili 2, pri čemu je TCR specifičan za peptide iz bilo kojeg Zahtjeva od 1 ili 2 te se može dobiti od citotoksičnih limfocita (CTL-a) iz Zahtjeva 16.
18. Nukleinska kiselina koja kodira receptor T stanica (TCR) prema Zahtjevu 17 ili vektor ekspresije sposoban za ekspresiju spomenutog receptora T stanice (TCR).
19. Uporaba citotoksičnih T limfocita kao što je definirano u Zahtjevu 16 u proizvodnji lijekova za eliminaciju stanica raka kod pacijenta čije stanice raka abnormalno eksprimiraju polipeptid koji se sastoji od aminokiselinskog slijeda prikazanog u bilo kojem od Zahtjeva 1 ili 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05019254A EP1760088B1 (en) | 2005-09-05 | 2005-09-05 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| PCT/EP2006/008642 WO2007028574A2 (en) | 2005-09-05 | 2006-09-05 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100128T1 true HRP20100128T1 (hr) | 2010-04-30 |
Family
ID=35170099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100128T HRP20100128T1 (hr) | 2005-09-05 | 2006-09-05 | Tumoru pridruženi peptid koji se slobodno veže na molekule humanog leukocitnog antigena (hla) klase ii |
| HR20110981T HRP20110981T1 (hr) | 2005-09-05 | 2011-12-30 | Tumoru pridruženi peptidi koji se slobodno vežu na molekule ljudskog leukocitnog antigena (hla) klasa ii |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110981T HRP20110981T1 (hr) | 2005-09-05 | 2011-12-30 | Tumoru pridruženi peptidi koji se slobodno vežu na molekule ljudskog leukocitnog antigena (hla) klasa ii |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US10196432B2 (hr) |
| EP (6) | EP1806359B1 (hr) |
| JP (1) | JP5627180B2 (hr) |
| KR (3) | KR101386790B1 (hr) |
| CN (3) | CN105440119A (hr) |
| AT (5) | ATE461214T1 (hr) |
| AU (2) | AU2006289290B2 (hr) |
| BR (1) | BRPI0615462A2 (hr) |
| CA (2) | CA2929252A1 (hr) |
| CY (5) | CY1107973T1 (hr) |
| DE (4) | DE602005020047D1 (hr) |
| DK (5) | DK1806359T3 (hr) |
| EA (1) | EA013876B1 (hr) |
| ES (5) | ES2341295T3 (hr) |
| HK (1) | HK1220709A1 (hr) |
| HR (2) | HRP20100128T1 (hr) |
| NO (1) | NO340870B1 (hr) |
| NZ (2) | NZ588813A (hr) |
| PL (5) | PL1806358T3 (hr) |
| PT (5) | PT1806359E (hr) |
| SI (5) | SI1760088T1 (hr) |
| UA (1) | UA98295C2 (hr) |
| WO (1) | WO2007028574A2 (hr) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1806358T3 (pl) * | 2005-09-05 | 2010-08-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| PL2567707T3 (pl) | 2007-07-27 | 2017-03-31 | Immatics Biotechnologies Gmbh | Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi |
| UA103751C2 (ru) | 2007-07-27 | 2013-11-25 | Имматикс Биотекнолоджис Гмбх | Иммуногенный пептид для иммунотерапии |
| US8455444B2 (en) * | 2007-08-20 | 2013-06-04 | Oncotherapy Science, Inc. | CDH3 peptide and medicinal agent comprising the same |
| WO2009059011A2 (en) * | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
| PL2105501T3 (pl) | 2008-03-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu |
| DE602008000891D1 (de) | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| PT2172211E (pt) * | 2008-10-01 | 2015-03-09 | Immatics Biotechnologies Gmbh | Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer |
| DK2623517T3 (en) | 2009-01-28 | 2015-11-23 | Ind Tech Res Inst | Urine and serum biomarkers associated with diabetic nephropathy |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN103547283A (zh) | 2010-12-14 | 2014-01-29 | 伊玛提克斯生物技术有限公司 | 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 |
| EP2689010B1 (en) * | 2011-03-23 | 2020-11-18 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| PT3456339T (pt) | 2013-08-05 | 2021-12-09 | Immatics Biotechnologies Gmbh | Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc |
| TWI636065B (zh) | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| HRP20191671T1 (hr) | 2014-05-09 | 2019-12-13 | Immatics Biotechnologies Gmbh | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| HUE056607T2 (hu) | 2014-12-23 | 2022-02-28 | Immatics Biotechnologies Gmbh | Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| PT3388075T (pt) | 2015-03-27 | 2023-08-18 | Immatics Biotechnologies Gmbh | Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP2018518956A (ja) * | 2015-06-19 | 2018-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法 |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MD3319985T2 (ro) | 2015-07-06 | 2021-01-31 | Immatics Biotechnologies Gmbh | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere |
| MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| IL292864A (en) | 2015-08-28 | 2022-07-01 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| HK1255541A1 (zh) | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| MA54832A (fr) | 2016-03-01 | 2021-12-01 | Immatics Biotechnologies Gmbh | Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| TWI837869B (zh) * | 2016-03-31 | 2024-04-01 | 美商百歐恩泰美國公司 | 新抗原及其使用方法 |
| JP6989136B2 (ja) | 2016-04-06 | 2022-01-05 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ |
| CR20200607A (es) | 2016-04-21 | 2021-01-20 | Immatics Biotechnologies Gmbh | INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551) |
| CA3021159A1 (en) | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| HUE068936T2 (hu) * | 2016-06-10 | 2025-02-28 | Gadeta B V | Új eljárás tumorellenes vagy fertõzés elleni választ közvetítõ deltaT-sejt- (vagy gammaT-sejt-) receptor-láncok vagy azok részeinek azonosítására |
| TW202304970A (zh) | 2016-08-26 | 2023-02-01 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| SG10202108122YA (en) | 2017-01-27 | 2021-09-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA47367B1 (fr) | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| CN110248672A (zh) * | 2017-02-06 | 2019-09-17 | 中央研究院 | 重组蛋白及其用途 |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| KR20190137858A (ko) | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 |
| WO2018189152A2 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| KR20190137829A (ko) | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 암에 대한 면역요법에서의 사용을 위한 펩티드 및 그 조합 |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| TW201906859A (zh) | 2017-07-07 | 2019-02-16 | 德商英麥提克生物技術股份有限公司 | 用於肺癌（包括 nsclc、sclc 和其他癌症）免疫治療的新型肽和肽組合物 |
| JP7274462B2 (ja) | 2017-09-18 | 2023-05-16 | エスアンドピー・イングリーディエント・ディベロップメント・エルエルシー | 塩化カリウムを有する低ナトリウム塩代替物 |
| AU2018348165B2 (en) | 2017-10-10 | 2025-09-04 | Seattle Project Corp. | Neoantigen identification using hotspots |
| JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
| DE102018108996B4 (de) | 2018-02-09 | 2021-10-21 | Immatics US, Inc. | Verfahren zur Herstellung autologer T-Zellen |
| KR20200119840A (ko) | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CN119851752A (zh) * | 2018-02-27 | 2025-04-18 | 磨石生物公司 | 利用泛等位基因模型进行的新抗原鉴别 |
| EP3539562A1 (en) * | 2018-03-12 | 2019-09-18 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immunotherapeutic peptides |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| TW202028224A (zh) | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| MX2021015033A (es) | 2019-06-06 | 2022-01-18 | Immatics Biotechnologies Gmbh | Clasificacion con contraseleccion utilizando peptidos de secuencias similares. |
| CN110305209B (zh) * | 2019-07-09 | 2022-09-13 | 福建医科大学附属第一医院 | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 |
| AU2020320445A1 (en) * | 2019-07-30 | 2022-03-03 | University Health Network | T cell receptors and methods of use thereof |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| CN120712104A (zh) * | 2022-10-14 | 2025-09-26 | 广东天科雅生物医药科技有限公司 | 针对神经胶质瘤的肽疫苗及其用途 |
| CN117720620B (zh) * | 2023-12-13 | 2024-07-23 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212000B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8258260B2 (en) * | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| GR66050B (hr) * | 1977-09-20 | 1981-01-14 | Licinvest Ag | |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DK171727B1 (da) | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4810781A (en) | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| JPH07508403A (ja) * | 1992-04-03 | 1995-09-21 | ラ ホヤ キャンサー リサーチ ファウンデーション | デコリンフラグメントおよび細胞調節因子を阻害する方法 |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| CA2175380A1 (en) * | 1993-10-29 | 1995-05-04 | Lan Bo Chen | A novel tumor marker and novel method of isolating same |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| EP0769963A4 (en) | 1994-07-27 | 1999-07-28 | Commw Scient Ind Res Org | POLYEPITOPE VACCINES |
| UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
| AU1394497A (en) | 1996-01-17 | 1997-08-11 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US6610821B1 (en) * | 1996-07-12 | 2003-08-26 | Mcgill University | Compounds and methods for modulating endothelial cell adhesion |
| EP0988385A2 (en) * | 1997-01-21 | 2000-03-29 | Human Genome Sciences | Tace-like and matrilysin-like polypeptides |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| WO1999019477A1 (de) * | 1997-10-15 | 1999-04-22 | Forssmann Wolf Georg | Cadherin derived growth factor und seine verwendung |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| US6746852B1 (en) * | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| DE19938583A1 (de) | 1999-08-18 | 2001-02-22 | Buehler Ag | Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial |
| GB2373500B (en) * | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2002008262A2 (en) * | 2000-07-26 | 2002-01-31 | Stanford University | Bstp-5 proteins and related reagents and methods of use thereof |
| WO2002050103A2 (en) | 2000-12-20 | 2002-06-27 | Glaxosmithkline Biologicals S.A. | Tumour-related antigens |
| WO2002078516A2 (en) * | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| WO2003004989A2 (en) * | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7087727B2 (en) * | 2001-08-13 | 2006-08-08 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| AU2002335824A1 (en) * | 2001-10-12 | 2003-04-22 | Case Western Reserve University | Neuronal regeneration |
| WO2003068940A2 (en) * | 2002-02-14 | 2003-08-21 | Curagen Corporation | Complexes and methods of using same |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| AU2002368151A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES |
| US7601505B2 (en) * | 2003-05-29 | 2009-10-13 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20080227125A1 (en) * | 2003-07-15 | 2008-09-18 | Guilaine Argoud-Puy | Secreted Polypeptide Species Reduced in Cardiovascular Disorders |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| ES2330013T3 (es) * | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| PL1806358T3 (pl) * | 2005-09-05 | 2010-08-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II |
| EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
-
2005
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
-
2006
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en active Application Filing
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
-
2007
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
-
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
-
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
-
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
-
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
-
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100128T1 (hr) | Tumoru pridruženi peptid koji se slobodno veže na molekule humanog leukocitnog antigena (hla) klase ii | |
| HRP20201228T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
| HRP20170718T1 (hr) | Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni i gastrični karcinom | |
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2020198875A5 (hr) | ||
| JP2009506762A5 (hr) | ||
| JP2013521789A5 (hr) | ||
| JP2020182458A5 (hr) | ||
| JP2020191862A5 (hr) | ||
| JP2010534463A5 (hr) | ||
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
| JP2017525336A5 (hr) | ||
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2020506690A5 (hr) | ||
| JP2017524337A5 (hr) | ||
| JP2020516681A5 (hr) | ||
| Sultan et al. | Role of MDA5 and interferon-I in dendritic cells for T cell expansion by anti-tumor peptide vaccines in mice | |
| JP2019536426A5 (hr) | ||
| Cho et al. | An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects | |
| US20210363543A1 (en) | Self Replicating RNA System | |
| CN114072166A (zh) | 用于治疗t细胞耗竭的组合物和方法 | |
| JP2020191873A5 (hr) | ||
| HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |